XML 61 R45.htm IDEA: XBRL DOCUMENT
v3.24.1

Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022
--- | --- | ---
Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items] |  |
Gross Carrying Amount | $ 7,969 | $ 8,541
Accumulated Amortization | 1,871 | 1,598
Net | 6,098 | 6,943
Hormone Therapy Drug Patents [Member] |  |
Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items] |  |
Gross Carrying Amount | 6,818 | 6,225
Accumulated Amortization | 1,871 | 1,598
Net | 4,947 | 4,627
Hormone therapy drug patents applied and pending approval [Member] |  |
Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items] |  |
Gross Carrying Amount | 842 | 1,995
Accumulated Amortization |  |
Net | 842 | 1,995
Intangible Assets Subject to Amortization [Member] |  |
Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items] |  |
Gross Carrying Amount | 7,660 | 8,220
Accumulated Amortization | 1,871 | 1,598
Net | 5,789 | 6,622
Trademarks and Trade Names [Member] |  |
Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items] |  |
Gross Carrying Amount | 309 | 321
Accumulated Amortization |  |
Net | $ 309 | $ 321

X
- References No definition available. + Details
Name: | txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems
Namespace Prefix: | txmd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before accumulated amortization of intangible assets, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_IntangibleAssetsGrossExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_IntangibleAssetsSubjectToAmortizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |